Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?
The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) c...
Gespeichert in:
| Veröffentlicht in: | Journal of electrocardiology 2017-11, Vol.50 (6), p.825-827 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 827 |
|---|---|
| container_issue | 6 |
| container_start_page | 825 |
| container_title | Journal of electrocardiology |
| container_volume | 50 |
| creator | Mason, Jay W. |
| description | The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) commercialization of the testing methods, (4) quantitative understanding of arrhythmia risk of the 6 non-hERG channels being tested, (5) validity of the CiPA drug list, and (6) ultimate clinical validation. |
| doi_str_mv | 10.1016/j.jelectrocard.2017.08.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1940195562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022073617302522</els_id><sourcerecordid>1940195562</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-6d466a7ef556f1421bfa069326d90303c343807884f2d7b518cee700be756c163</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhi0EokvhFZAFB7gkHTuJ7eylqpZSKlVwgbPl2BPqNIkXO9uyb4-rLVXFiZMl65t_Rv9HyDsGJQMmToZywBHtEoM10ZUcmCxBlcDYM7JiTcULVVfwnKwAOC9AVuKIvEppAICWS_6SHHHVspYztSK_NznChzH89Gn5kOg2-Hmhoae3Hu_W9Gu4xZGeby5o58Nk4g3GRM3sqJ9p8qO3gU7B4ZhoHyLdxmBivN4v15O3NPp0k7_Qebv4MK_pWUR6hzSicfvT1-RFb8aEbx7eY_Lj8_n3zZfi6tvF5ebsqrA1qKUQrhbCSOybRvSs5qzrDYi24sK1UEFlq7pSIJWqe-5k1zBlESVAh7IRlonqmHw85Objfu0wLXryyeI4mhnDLmnW1sDanM4z-v4fdAi7OOfrNAcpG9k0bZup9YGyMaQUsdfb6HM1e81A3_vRg37qR9_70aB09pOH3z6s2HUTusfRv0Iy8OkA5E4xO4g6WY-zzS3GHKld8P-z5w__nKeC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2077575599</pqid></control><display><type>article</type><title>Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mason, Jay W.</creator><creatorcontrib>Mason, Jay W.</creatorcontrib><description>The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) commercialization of the testing methods, (4) quantitative understanding of arrhythmia risk of the 6 non-hERG channels being tested, (5) validity of the CiPA drug list, and (6) ultimate clinical validation.</description><identifier>ISSN: 0022-0736</identifier><identifier>EISSN: 1532-8430</identifier><identifier>DOI: 10.1016/j.jelectrocard.2017.08.011</identifier><identifier>PMID: 28919218</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biomarkers - analysis ; Cardiology ; Cardiovascular disease ; Drug Evaluation, Preclinical - methods ; Electrocardiography ; Heart Conduction System - drug effects ; hERG channel ; Humans ; Ion Channels - drug effects ; Long QT Syndrome - chemically induced ; Long QT Syndrome - diagnosis ; Predictive Value of Tests ; Proarrhythmia ; QT prolongation ; Risk Assessment ; Torsades de pointes ; Torsades de Pointes - chemically induced ; Torsades de Pointes - diagnosis</subject><ispartof>Journal of electrocardiology, 2017-11, Vol.50 (6), p.825-827</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Nov/Dec 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-6d466a7ef556f1421bfa069326d90303c343807884f2d7b518cee700be756c163</citedby><cites>FETCH-LOGICAL-c408t-6d466a7ef556f1421bfa069326d90303c343807884f2d7b518cee700be756c163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022073617302522$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28919218$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mason, Jay W.</creatorcontrib><title>Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?</title><title>Journal of electrocardiology</title><addtitle>J Electrocardiol</addtitle><description>The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) commercialization of the testing methods, (4) quantitative understanding of arrhythmia risk of the 6 non-hERG channels being tested, (5) validity of the CiPA drug list, and (6) ultimate clinical validation.</description><subject>Biomarkers - analysis</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Electrocardiography</subject><subject>Heart Conduction System - drug effects</subject><subject>hERG channel</subject><subject>Humans</subject><subject>Ion Channels - drug effects</subject><subject>Long QT Syndrome - chemically induced</subject><subject>Long QT Syndrome - diagnosis</subject><subject>Predictive Value of Tests</subject><subject>Proarrhythmia</subject><subject>QT prolongation</subject><subject>Risk Assessment</subject><subject>Torsades de pointes</subject><subject>Torsades de Pointes - chemically induced</subject><subject>Torsades de Pointes - diagnosis</subject><issn>0022-0736</issn><issn>1532-8430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhi0EokvhFZAFB7gkHTuJ7eylqpZSKlVwgbPl2BPqNIkXO9uyb4-rLVXFiZMl65t_Rv9HyDsGJQMmToZywBHtEoM10ZUcmCxBlcDYM7JiTcULVVfwnKwAOC9AVuKIvEppAICWS_6SHHHVspYztSK_NznChzH89Gn5kOg2-Hmhoae3Hu_W9Gu4xZGeby5o58Nk4g3GRM3sqJ9p8qO3gU7B4ZhoHyLdxmBivN4v15O3NPp0k7_Qebv4MK_pWUR6hzSicfvT1-RFb8aEbx7eY_Lj8_n3zZfi6tvF5ebsqrA1qKUQrhbCSOybRvSs5qzrDYi24sK1UEFlq7pSIJWqe-5k1zBlESVAh7IRlonqmHw85Objfu0wLXryyeI4mhnDLmnW1sDanM4z-v4fdAi7OOfrNAcpG9k0bZup9YGyMaQUsdfb6HM1e81A3_vRg37qR9_70aB09pOH3z6s2HUTusfRv0Iy8OkA5E4xO4g6WY-zzS3GHKld8P-z5w__nKeC</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Mason, Jay W.</creator><general>Elsevier Inc</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201711</creationdate><title>Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?</title><author>Mason, Jay W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-6d466a7ef556f1421bfa069326d90303c343807884f2d7b518cee700be756c163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biomarkers - analysis</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Electrocardiography</topic><topic>Heart Conduction System - drug effects</topic><topic>hERG channel</topic><topic>Humans</topic><topic>Ion Channels - drug effects</topic><topic>Long QT Syndrome - chemically induced</topic><topic>Long QT Syndrome - diagnosis</topic><topic>Predictive Value of Tests</topic><topic>Proarrhythmia</topic><topic>QT prolongation</topic><topic>Risk Assessment</topic><topic>Torsades de pointes</topic><topic>Torsades de Pointes - chemically induced</topic><topic>Torsades de Pointes - diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mason, Jay W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of electrocardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mason, Jay W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?</atitle><jtitle>Journal of electrocardiology</jtitle><addtitle>J Electrocardiol</addtitle><date>2017-11</date><risdate>2017</risdate><volume>50</volume><issue>6</issue><spage>825</spage><epage>827</epage><pages>825-827</pages><issn>0022-0736</issn><eissn>1532-8430</eissn><abstract>The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) commercialization of the testing methods, (4) quantitative understanding of arrhythmia risk of the 6 non-hERG channels being tested, (5) validity of the CiPA drug list, and (6) ultimate clinical validation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28919218</pmid><doi>10.1016/j.jelectrocard.2017.08.011</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-0736 |
| ispartof | Journal of electrocardiology, 2017-11, Vol.50 (6), p.825-827 |
| issn | 0022-0736 1532-8430 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1940195562 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biomarkers - analysis Cardiology Cardiovascular disease Drug Evaluation, Preclinical - methods Electrocardiography Heart Conduction System - drug effects hERG channel Humans Ion Channels - drug effects Long QT Syndrome - chemically induced Long QT Syndrome - diagnosis Predictive Value of Tests Proarrhythmia QT prolongation Risk Assessment Torsades de pointes Torsades de Pointes - chemically induced Torsades de Pointes - diagnosis |
| title | Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A00%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiologist's%20point%20of%20view:%20Novel%20ECG%20biomarkers%20and%20in%20silico%20models%20for%20proarrhythmic%20risk%20prediction:%20Are%20we%20ready?&rft.jtitle=Journal%20of%20electrocardiology&rft.au=Mason,%20Jay%20W.&rft.date=2017-11&rft.volume=50&rft.issue=6&rft.spage=825&rft.epage=827&rft.pages=825-827&rft.issn=0022-0736&rft.eissn=1532-8430&rft_id=info:doi/10.1016/j.jelectrocard.2017.08.011&rft_dat=%3Cproquest_cross%3E1940195562%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2077575599&rft_id=info:pmid/28919218&rft_els_id=S0022073617302522&rfr_iscdi=true |